Species identification of Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65 , and susceptibility testing to eight antibiotics
Summary Objectives To separate Mycobacterium abscessus subsp. bolletii from Mycobacterium abscessus subsp. abscessus using species identification, and to investigate the in vitro activity of amikacin, cefoxitin, imipenem, levofloxacin, moxifloxacin, clarithromycin, azithromycin, and linezolid agains...
Gespeichert in:
| Veröffentlicht in: | International journal of infectious diseases 2014-08, Vol.25, p.170-174 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 174 |
|---|---|
| container_issue | |
| container_start_page | 170 |
| container_title | International journal of infectious diseases |
| container_volume | 25 |
| creator | Nie, Wenjuan Duan, Hongfei Huang, Hairong Lu, Yu Bi, Dapeng Chu, Naihui |
| description | Summary Objectives To separate Mycobacterium abscessus subsp. bolletii from Mycobacterium abscessus subsp. abscessus using species identification, and to investigate the in vitro activity of amikacin, cefoxitin, imipenem, levofloxacin, moxifloxacin, clarithromycin, azithromycin, and linezolid against Mycobacterium abscessus. Methods Seventy M. abscessus isolates, previously identified by 16S rRNA sequencing, were further identified by comparative sequence analysis of rpoB and hsp65 . Drug susceptibility testing was conducted using the microplate Alamar Blue assay in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines and interpreted using CLSI breakpoints. Results Of the 70 strains, 45 (64%) were M. abscessus subsp. abscessus and 25 (36%) were M. abscessus subsp. bolletii . The majority of M. abscessus isolates were susceptible to azithromycin, amikacin, linezolid, and imipenem ( M. abscessus subsp. abscessus : 93%, 98%, 93%, and 73%, respectively; M. abscessus subsp. bolletii : 96%, 96%, 80%, and 68%, respectively). Approximately half of the M. abscessus isolates were moderately susceptible to cefoxitin and moxifloxacin ( M. abscessus subsp. abscessus 53% and 49%; M. abscessus subsp. bolletii 72% and 68%). Nearly all the M. abscessus isolates were resistant to levofloxacin ( M. abscessus subsp. abscessus 96%, M. abscessus subsp. bolletii 100%). Inducible clarithromycin resistance was found in M. abscessus . After 14 days of incubation, 83% M. abscessus subsp. abscessus and 36% M. abscessus subsp. bolletii were resistant to clarithromycin. Conclusions Using rpoB and hsp65 , M. abscessus subsp. bolletii could be distinguished from M. abscessus subsp. abscessus. Amikacin and azithromycin showed excellent activity against M. abscessus in vitro. Imipenem, linezolid, cefoxitin, and moxifloxacin also showed good activity. Levofloxacin was inactive against M. abscessus. Although clarithromycin showed excellent activity against M. abscessus on day 3, inducible resistance occurred, and after 14 days clarithromycin showed little activity against M. abscessus subsp. abscessus , but still had good activity against M. abscessus subsp. bolletii. |
| doi_str_mv | 10.1016/j.ijid.2014.02.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1548636952</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1201971214014520</els_id><sourcerecordid>1548636952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c455t-3162ecb3711b53bb7c859eaedc1eb60fad335fc19ea7d076dcfb6cf2686d1ebb3</originalsourceid><addsrcrecordid>eNqFkstu1TAQhiMEoqXwAixQlixI8CV2ciSEBBU3qYhFYW3F9qSdkBMHj4N0Hoz3w-kpCLGA1Yxmvn809j9F8ZizmjOun481juhrwXhTM1HncKc45V3bVVJxfjfnuVXtWi5OigdEI2Os0bq7X5yIZidFp_Rp8eNyAYdAJXqYEw7o-oRhLsNQfjy4YHuXIOK6L3tLDohWKmm1tNR_FPrZ_w-2YZogIZYr4XxVxiW8vpFd06JV-ewmz7iDJaHFCdOhTEBpY1MoAa-uU2a2Xkjo6GFxb-gngke38az48vbN5_P31cWndx_OX11UrlEqVZJrAc7KlnOrpLWt69QOevCOg9Vs6L2UanA811rPWu3dYLUbhO60z4SVZ8XT49wlhm9rXsjsMS85Tf0MYSXDVdNpqXdKZFQcURcDUYTBLBH3fTwYzsxmlxnNZpfZ7DJMmByy6Mnt_NXuwf-W_PInAy-OAORXfkeIhrJbswOPEVwyPuC_57_8S-4mnLPH01c4AI1hjXP-P8MNZYG53A5muxfeZLUSTP4EUp3BCQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1548636952</pqid></control><display><type>article</type><title>Species identification of Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65 , and susceptibility testing to eight antibiotics</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Nie, Wenjuan ; Duan, Hongfei ; Huang, Hairong ; Lu, Yu ; Bi, Dapeng ; Chu, Naihui</creator><creatorcontrib>Nie, Wenjuan ; Duan, Hongfei ; Huang, Hairong ; Lu, Yu ; Bi, Dapeng ; Chu, Naihui</creatorcontrib><description>Summary Objectives To separate Mycobacterium abscessus subsp. bolletii from Mycobacterium abscessus subsp. abscessus using species identification, and to investigate the in vitro activity of amikacin, cefoxitin, imipenem, levofloxacin, moxifloxacin, clarithromycin, azithromycin, and linezolid against Mycobacterium abscessus. Methods Seventy M. abscessus isolates, previously identified by 16S rRNA sequencing, were further identified by comparative sequence analysis of rpoB and hsp65 . Drug susceptibility testing was conducted using the microplate Alamar Blue assay in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines and interpreted using CLSI breakpoints. Results Of the 70 strains, 45 (64%) were M. abscessus subsp. abscessus and 25 (36%) were M. abscessus subsp. bolletii . The majority of M. abscessus isolates were susceptible to azithromycin, amikacin, linezolid, and imipenem ( M. abscessus subsp. abscessus : 93%, 98%, 93%, and 73%, respectively; M. abscessus subsp. bolletii : 96%, 96%, 80%, and 68%, respectively). Approximately half of the M. abscessus isolates were moderately susceptible to cefoxitin and moxifloxacin ( M. abscessus subsp. abscessus 53% and 49%; M. abscessus subsp. bolletii 72% and 68%). Nearly all the M. abscessus isolates were resistant to levofloxacin ( M. abscessus subsp. abscessus 96%, M. abscessus subsp. bolletii 100%). Inducible clarithromycin resistance was found in M. abscessus . After 14 days of incubation, 83% M. abscessus subsp. abscessus and 36% M. abscessus subsp. bolletii were resistant to clarithromycin. Conclusions Using rpoB and hsp65 , M. abscessus subsp. bolletii could be distinguished from M. abscessus subsp. abscessus. Amikacin and azithromycin showed excellent activity against M. abscessus in vitro. Imipenem, linezolid, cefoxitin, and moxifloxacin also showed good activity. Levofloxacin was inactive against M. abscessus. Although clarithromycin showed excellent activity against M. abscessus on day 3, inducible resistance occurred, and after 14 days clarithromycin showed little activity against M. abscessus subsp. abscessus , but still had good activity against M. abscessus subsp. bolletii.</description><identifier>ISSN: 1201-9712</identifier><identifier>EISSN: 1878-3511</identifier><identifier>DOI: 10.1016/j.ijid.2014.02.014</identifier><identifier>PMID: 24932856</identifier><language>eng</language><publisher>Canada: Elsevier Ltd</publisher><subject>Antibiotics, Antitubercular - pharmacology ; Bacterial Proteins - genetics ; Chaperonin 60 - genetics ; Clarithromycin ; Genotyping Techniques ; Humans ; Inducible resistance ; Infectious Disease ; Microbial Sensitivity Tests ; Mycobacterium abscessus subsp. abscessus ; Mycobacterium abscessus subsp. bolletii ; Mycobacterium Infections, Nontuberculous - microbiology ; Nontuberculous Mycobacteria - classification ; Nontuberculous Mycobacteria - drug effects ; Nontuberculous Mycobacteria - genetics ; Nontuberculous Mycobacteria - growth & development ; Phenotype ; Polymerase Chain Reaction ; Pulmonary/Respiratory ; RNA, Ribosomal, 16S - genetics ; Sputum - microbiology ; Susceptibility testing</subject><ispartof>International journal of infectious diseases, 2014-08, Vol.25, p.170-174</ispartof><rights>The Authors</rights><rights>2014 The Authors</rights><rights>Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c455t-3162ecb3711b53bb7c859eaedc1eb60fad335fc19ea7d076dcfb6cf2686d1ebb3</citedby><cites>FETCH-LOGICAL-c455t-3162ecb3711b53bb7c859eaedc1eb60fad335fc19ea7d076dcfb6cf2686d1ebb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijid.2014.02.014$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,861,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24932856$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nie, Wenjuan</creatorcontrib><creatorcontrib>Duan, Hongfei</creatorcontrib><creatorcontrib>Huang, Hairong</creatorcontrib><creatorcontrib>Lu, Yu</creatorcontrib><creatorcontrib>Bi, Dapeng</creatorcontrib><creatorcontrib>Chu, Naihui</creatorcontrib><title>Species identification of Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65 , and susceptibility testing to eight antibiotics</title><title>International journal of infectious diseases</title><addtitle>Int J Infect Dis</addtitle><description>Summary Objectives To separate Mycobacterium abscessus subsp. bolletii from Mycobacterium abscessus subsp. abscessus using species identification, and to investigate the in vitro activity of amikacin, cefoxitin, imipenem, levofloxacin, moxifloxacin, clarithromycin, azithromycin, and linezolid against Mycobacterium abscessus. Methods Seventy M. abscessus isolates, previously identified by 16S rRNA sequencing, were further identified by comparative sequence analysis of rpoB and hsp65 . Drug susceptibility testing was conducted using the microplate Alamar Blue assay in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines and interpreted using CLSI breakpoints. Results Of the 70 strains, 45 (64%) were M. abscessus subsp. abscessus and 25 (36%) were M. abscessus subsp. bolletii . The majority of M. abscessus isolates were susceptible to azithromycin, amikacin, linezolid, and imipenem ( M. abscessus subsp. abscessus : 93%, 98%, 93%, and 73%, respectively; M. abscessus subsp. bolletii : 96%, 96%, 80%, and 68%, respectively). Approximately half of the M. abscessus isolates were moderately susceptible to cefoxitin and moxifloxacin ( M. abscessus subsp. abscessus 53% and 49%; M. abscessus subsp. bolletii 72% and 68%). Nearly all the M. abscessus isolates were resistant to levofloxacin ( M. abscessus subsp. abscessus 96%, M. abscessus subsp. bolletii 100%). Inducible clarithromycin resistance was found in M. abscessus . After 14 days of incubation, 83% M. abscessus subsp. abscessus and 36% M. abscessus subsp. bolletii were resistant to clarithromycin. Conclusions Using rpoB and hsp65 , M. abscessus subsp. bolletii could be distinguished from M. abscessus subsp. abscessus. Amikacin and azithromycin showed excellent activity against M. abscessus in vitro. Imipenem, linezolid, cefoxitin, and moxifloxacin also showed good activity. Levofloxacin was inactive against M. abscessus. Although clarithromycin showed excellent activity against M. abscessus on day 3, inducible resistance occurred, and after 14 days clarithromycin showed little activity against M. abscessus subsp. abscessus , but still had good activity against M. abscessus subsp. bolletii.</description><subject>Antibiotics, Antitubercular - pharmacology</subject><subject>Bacterial Proteins - genetics</subject><subject>Chaperonin 60 - genetics</subject><subject>Clarithromycin</subject><subject>Genotyping Techniques</subject><subject>Humans</subject><subject>Inducible resistance</subject><subject>Infectious Disease</subject><subject>Microbial Sensitivity Tests</subject><subject>Mycobacterium abscessus subsp. abscessus</subject><subject>Mycobacterium abscessus subsp. bolletii</subject><subject>Mycobacterium Infections, Nontuberculous - microbiology</subject><subject>Nontuberculous Mycobacteria - classification</subject><subject>Nontuberculous Mycobacteria - drug effects</subject><subject>Nontuberculous Mycobacteria - genetics</subject><subject>Nontuberculous Mycobacteria - growth & development</subject><subject>Phenotype</subject><subject>Polymerase Chain Reaction</subject><subject>Pulmonary/Respiratory</subject><subject>RNA, Ribosomal, 16S - genetics</subject><subject>Sputum - microbiology</subject><subject>Susceptibility testing</subject><issn>1201-9712</issn><issn>1878-3511</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkstu1TAQhiMEoqXwAixQlixI8CV2ciSEBBU3qYhFYW3F9qSdkBMHj4N0Hoz3w-kpCLGA1Yxmvn809j9F8ZizmjOun481juhrwXhTM1HncKc45V3bVVJxfjfnuVXtWi5OigdEI2Os0bq7X5yIZidFp_Rp8eNyAYdAJXqYEw7o-oRhLsNQfjy4YHuXIOK6L3tLDohWKmm1tNR_FPrZ_w-2YZogIZYr4XxVxiW8vpFd06JV-ewmz7iDJaHFCdOhTEBpY1MoAa-uU2a2Xkjo6GFxb-gngke38az48vbN5_P31cWndx_OX11UrlEqVZJrAc7KlnOrpLWt69QOevCOg9Vs6L2UanA811rPWu3dYLUbhO60z4SVZ8XT49wlhm9rXsjsMS85Tf0MYSXDVdNpqXdKZFQcURcDUYTBLBH3fTwYzsxmlxnNZpfZ7DJMmByy6Mnt_NXuwf-W_PInAy-OAORXfkeIhrJbswOPEVwyPuC_57_8S-4mnLPH01c4AI1hjXP-P8MNZYG53A5muxfeZLUSTP4EUp3BCQ</recordid><startdate>20140801</startdate><enddate>20140801</enddate><creator>Nie, Wenjuan</creator><creator>Duan, Hongfei</creator><creator>Huang, Hairong</creator><creator>Lu, Yu</creator><creator>Bi, Dapeng</creator><creator>Chu, Naihui</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140801</creationdate><title>Species identification of Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65 , and susceptibility testing to eight antibiotics</title><author>Nie, Wenjuan ; Duan, Hongfei ; Huang, Hairong ; Lu, Yu ; Bi, Dapeng ; Chu, Naihui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c455t-3162ecb3711b53bb7c859eaedc1eb60fad335fc19ea7d076dcfb6cf2686d1ebb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antibiotics, Antitubercular - pharmacology</topic><topic>Bacterial Proteins - genetics</topic><topic>Chaperonin 60 - genetics</topic><topic>Clarithromycin</topic><topic>Genotyping Techniques</topic><topic>Humans</topic><topic>Inducible resistance</topic><topic>Infectious Disease</topic><topic>Microbial Sensitivity Tests</topic><topic>Mycobacterium abscessus subsp. abscessus</topic><topic>Mycobacterium abscessus subsp. bolletii</topic><topic>Mycobacterium Infections, Nontuberculous - microbiology</topic><topic>Nontuberculous Mycobacteria - classification</topic><topic>Nontuberculous Mycobacteria - drug effects</topic><topic>Nontuberculous Mycobacteria - genetics</topic><topic>Nontuberculous Mycobacteria - growth & development</topic><topic>Phenotype</topic><topic>Polymerase Chain Reaction</topic><topic>Pulmonary/Respiratory</topic><topic>RNA, Ribosomal, 16S - genetics</topic><topic>Sputum - microbiology</topic><topic>Susceptibility testing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nie, Wenjuan</creatorcontrib><creatorcontrib>Duan, Hongfei</creatorcontrib><creatorcontrib>Huang, Hairong</creatorcontrib><creatorcontrib>Lu, Yu</creatorcontrib><creatorcontrib>Bi, Dapeng</creatorcontrib><creatorcontrib>Chu, Naihui</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nie, Wenjuan</au><au>Duan, Hongfei</au><au>Huang, Hairong</au><au>Lu, Yu</au><au>Bi, Dapeng</au><au>Chu, Naihui</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Species identification of Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65 , and susceptibility testing to eight antibiotics</atitle><jtitle>International journal of infectious diseases</jtitle><addtitle>Int J Infect Dis</addtitle><date>2014-08-01</date><risdate>2014</risdate><volume>25</volume><spage>170</spage><epage>174</epage><pages>170-174</pages><issn>1201-9712</issn><eissn>1878-3511</eissn><abstract>Summary Objectives To separate Mycobacterium abscessus subsp. bolletii from Mycobacterium abscessus subsp. abscessus using species identification, and to investigate the in vitro activity of amikacin, cefoxitin, imipenem, levofloxacin, moxifloxacin, clarithromycin, azithromycin, and linezolid against Mycobacterium abscessus. Methods Seventy M. abscessus isolates, previously identified by 16S rRNA sequencing, were further identified by comparative sequence analysis of rpoB and hsp65 . Drug susceptibility testing was conducted using the microplate Alamar Blue assay in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines and interpreted using CLSI breakpoints. Results Of the 70 strains, 45 (64%) were M. abscessus subsp. abscessus and 25 (36%) were M. abscessus subsp. bolletii . The majority of M. abscessus isolates were susceptible to azithromycin, amikacin, linezolid, and imipenem ( M. abscessus subsp. abscessus : 93%, 98%, 93%, and 73%, respectively; M. abscessus subsp. bolletii : 96%, 96%, 80%, and 68%, respectively). Approximately half of the M. abscessus isolates were moderately susceptible to cefoxitin and moxifloxacin ( M. abscessus subsp. abscessus 53% and 49%; M. abscessus subsp. bolletii 72% and 68%). Nearly all the M. abscessus isolates were resistant to levofloxacin ( M. abscessus subsp. abscessus 96%, M. abscessus subsp. bolletii 100%). Inducible clarithromycin resistance was found in M. abscessus . After 14 days of incubation, 83% M. abscessus subsp. abscessus and 36% M. abscessus subsp. bolletii were resistant to clarithromycin. Conclusions Using rpoB and hsp65 , M. abscessus subsp. bolletii could be distinguished from M. abscessus subsp. abscessus. Amikacin and azithromycin showed excellent activity against M. abscessus in vitro. Imipenem, linezolid, cefoxitin, and moxifloxacin also showed good activity. Levofloxacin was inactive against M. abscessus. Although clarithromycin showed excellent activity against M. abscessus on day 3, inducible resistance occurred, and after 14 days clarithromycin showed little activity against M. abscessus subsp. abscessus , but still had good activity against M. abscessus subsp. bolletii.</abstract><cop>Canada</cop><pub>Elsevier Ltd</pub><pmid>24932856</pmid><doi>10.1016/j.ijid.2014.02.014</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1201-9712 |
| ispartof | International journal of infectious diseases, 2014-08, Vol.25, p.170-174 |
| issn | 1201-9712 1878-3511 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1548636952 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
| subjects | Antibiotics, Antitubercular - pharmacology Bacterial Proteins - genetics Chaperonin 60 - genetics Clarithromycin Genotyping Techniques Humans Inducible resistance Infectious Disease Microbial Sensitivity Tests Mycobacterium abscessus subsp. abscessus Mycobacterium abscessus subsp. bolletii Mycobacterium Infections, Nontuberculous - microbiology Nontuberculous Mycobacteria - classification Nontuberculous Mycobacteria - drug effects Nontuberculous Mycobacteria - genetics Nontuberculous Mycobacteria - growth & development Phenotype Polymerase Chain Reaction Pulmonary/Respiratory RNA, Ribosomal, 16S - genetics Sputum - microbiology Susceptibility testing |
| title | Species identification of Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii using rpoB and hsp65 , and susceptibility testing to eight antibiotics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T05%3A57%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Species%20identification%20of%20Mycobacterium%20abscessus%20subsp.%20abscessus%20and%20Mycobacterium%20abscessus%20subsp.%20bolletii%20using%20rpoB%20and%20hsp65%20,%20and%20susceptibility%20testing%20to%20eight%20antibiotics&rft.jtitle=International%20journal%20of%20infectious%20diseases&rft.au=Nie,%20Wenjuan&rft.date=2014-08-01&rft.volume=25&rft.spage=170&rft.epage=174&rft.pages=170-174&rft.issn=1201-9712&rft.eissn=1878-3511&rft_id=info:doi/10.1016/j.ijid.2014.02.014&rft_dat=%3Cproquest_cross%3E1548636952%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1548636952&rft_id=info:pmid/24932856&rft_els_id=1_s2_0_S1201971214014520&rfr_iscdi=true |